SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year
DUBLIN...

Related Keywords

Ireland ,University Of Pennsylvania ,Pennsylvania ,United States ,Philadelphia ,Canada ,Dublin ,Ryan Weispfenning ,Kimberly Powell ,Nina Goodheart ,Howardc Herrmann ,American College Of Cardiology ,Perelman School Of Medicine ,Edwards Lifesciences Corporation ,Exchange Commission ,Our Mission ,Medtronic ,Cardiology Annual ,New England Journal ,Annuli Randomized To Evolut ,Structural Heart ,Cardiovascular Portfolio ,Edwards Lifesciences ,Canada Newswire ,Markets ,